Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Hypoglycemic Agents

Hematinics

Antineoplastic Agents

Amino Acids

Antibodies

Antibodies, Monoclonal

Insulin

Insulin, Globin Zinc

Immunoglobulins

Liver Extracts

Mitogens

Sorafenib

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2

AVE1642 selected dose in combination with sorafenib

AVE1642 selected dose in combination with erlotinib

AVE1642

sorafenib

erlotinib

Olivier Rosmorduc, Professor

The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.

The secondary objectives of the study are:

* To evaluate the safety profile of AVE1642 as single agent and the safety profile of combinations with other anti-cancer therapies of interest in liver carcinoma , including detection of immunogenicity.
* To evaluate pharmacokinetics and pharmacodynamics profiles of AVE1642 as single agent or any PK interactions when given in combination with other anti-cancer therapies.
* To assess the preliminary clinical activity in terms of response rate (Complete response + Partial response), duration of responses, stabilisation rate and duration of stabilisation, according to RECIST criteria.
* To assess the biological activity at the tumor level.

AVE1642 will be administered as an IV infusion on day 1 and then every 3 weeks for at least 2 infusions for evaluability requirements. Curative and / or prophylactic management of allergic reactions during infusion will be implemented when needed. The duration of the study for one patient will include a period for inclusion of up to 2 weeks, at least 2 cycles of treatment in dose escalation step (one cycle of AVE1642 alone and at least one cycle of AVE1642 in combination) and at least one cycle of the combination in the extension cohort, followed, when possible, by a minimum of 30-day follow-up after the last drug administration, in order to detect any potential immunogenicity. In the second step, the patients will continue treatment until disease progression, unacceptable toxicity or willingness to stop.

The expected enrolment period is 15 months with at least 30 day follow-up after the last patient treated.

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Dose-finding, Safety, Pharmacokinetic and Pharmacodynamic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination With Other Anti Cancer Therapies (Sorafenib or Erlotinib) in Patients With Advanced Liver Carcinoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	NCT00791544	Liver Carcinoma	AVE1642 sorafenib erlotinib	18 Years -	Sanofi
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	NCT00791544	Liver Carcinoma	AVE1642 sorafenib erlotinib	18 Years -	Sanofi

Spots Global Cancer Trial Database for monoclonal antibody, anti igf1r